Redeye: Formpipe - On Track for 2025 Targets

Redeye retains its positive view of Formpipe following a solid Q1 report with robust ACV and early signs of the expected margin increases. We leave our forecasts and Base Case largely unchanged.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/